METHOD OF USING AN ANTI-CD137 ANTIBODY AS AN AGENT FOR RADIOIMMUNOTHERAPY OR RADIOIMMUNODETECTION

• US 20110104049A1
• Filed: 02/26/2010
• Published: 05/05/2011
• Est. Priority Date: 02/15/2005
• Status: Abandoned Application

• Current Assignee: GTC Biotherapeutics, Inc., Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: GTC Biotherapeutics, Inc., Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Echelard, Yann, Meade, Harry M., Schindler, Daniel, Strome, Scott E., Chen, Lieping
• Application Number:
  US12/713,731
• Publication Number:
  US 20110104049A1
• Time in Patent Office: Days
• US Class Current: 424/1.11
• CPC Class Codes: A61K 51/1096 radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis

Abstract

The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred embodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.

Claims

1. An antibody composition useful for radioimmunotherapy comprising an agonistic 4-1BB recombinant antibody, a radionuclide marker molecule and a conjugated toxin.

2. The antibody composition of claim 1, wherein said conjugated toxin is a toxin selected from the group consisting of single chain, two chain and multiple chain toxins.

3. The antibody composition of claim 1, wherein said radionuclide marker molecule is selected from the group consisting of beta emitters, alpha emitters and gamma emitters.

4. The antibody composition of claim 3, wherein said radionuclide marker molecule is a radioactive iodine isotope.

5. The antibody composition of claim 3, wherein said radionuclide marker molecule is selected from the group consisting of Yttrium-90 and Indium-111.

6. The antibody composition of claim 1, wherein said 4-1BB recombinant antibody is in the form of the fragments F(ab′

)2 and Fab.

8. The antibody composition of claim 1, wherein said conjugated toxin is a toxin selected from the group consisting of ricin toxin, diphtheria toxin, a venom toxin, and a bacterial toxin.

9. The antibody composition of claim 1, wherein said antibody composition is useful for modulating or treating at least one malignant disease in a cell, tissue, organ, animal or patient.

10. The antibody composition of claim 1, wherein said antibody composition is useful for modulating or treating at least one malignant disease in a cell, tissue, organ, animal or patient, said at least one malignant disease being selected from a group consisting of leukemia;

acute leukemia;

acute lymphoblastic leukemia (ALL);

B-cell, T-cell or FAB ALL;

acute myeloid leukemia (AML);

chromic myelocytic leukemia (CML);

chronic lymphocytic leukemia (CLL);

hairy cell leukemia;

myelodyplastic syndrome (MDS);

a lymphoma;

Hodgkin'"'"'s disease;

a malignant lymphoma;

non-hodgkin'"'"'s lymphoma;

Burkitt'"'"'s lymphoma;

multiple myeloma;

Kaposi'"'"'s sarcoma;

colorectal carcinoma;

pancreatic carcinoma;

nasopharyngeal carcinoma;

malignant histiocytosis;

paraneoplastic syndrome;

solid tumors;

adenocarcinomas;

sarcomas;

melanoma;

hemangioma; and

metastatic disease.

11. The antibody composition of claim 1, wherein said antibody composition is administered intravenously.

12. The antibody composition of claim 1, wherein said antibody composition is administered by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

17. The antibody composition of claim 1, wherein said radionuclide radioisotope is selected from the group consisting of Ac-225, Ag-111, As-72, As-77, At-211, Au-198, Au-199, Bi-212, Bi-213, Br-75, Br-76, C-11, C-55, Cu-62, Cu-64, Cu-67, Dy-166, Er-169, F-18, Fe-52, Fe-59, Ga-67, Ga-68, Gd-154, Gd-155, Gd-156, Gd-157, Gd-158, Ho-166, I-120, I-123, I-124, I-125, I-131, In-110, In-111, Ir-194, Lu-177, Mn-51, Mn-52m, Mo-99, N-13, O-15, P-32, P-33, Pb-211, Pb-212, Pd-109, Pm-149, Pr-142, Pr-143, Ra-223, Rb-82m, Re-186, Re-188, Re-189, Rh-105, Sc-47, Sm-153, Se-75, Sr-83, Sr-89, Tb-161, Tc-94m, Tc-94, Tc-99m, Y-86, Y-90, Y-88, and Zr-89.

19. The antibody composition of claim 1, wherein said antibody is thermodynamically stable under physiological conditions.

20. The antibody composition of claim 1, wherein said radionuclide is a gamma-emitting radionuclide.

7. (canceled)

13-16. -16. (canceled)

18. (canceled)